medigraphic.com
ISSN 0028-3851 (Print)

2017, Number 2

<< Back Next >>

Rev Neurol Neurocir Psiquiat 2017; 45 (2)

Symptomatic non-motor complex of Parkinson’s disease

Rodríguez-Violante M, Zerón-Martínez R, Cervantes-Arriaga A

Language: Spanish
References: 70
Page: 51-60
PDF size: 221.79 Kb.


ABSTRACT

Parkinson’s disease is characterized by well-recognized motor symptoms including rest tremor, rigidity, bradykinesia, and postural and gait disturbances. However, the disease is also accompanied by a large number of manifestations called non-motor symptoms. These symptoms include sleep disorders, autonomic and sensory disturbances, as well as neuropsychiatric symptoms. These non-motor symptoms have clinical relevance as they impact on the quality of life and patient’s perception of their own health. Moreover, this non-motor complex of the disease may precede the onset of motor symptoms, providing the opportunity to be used as biomarkers. As a result, it is important to know the diagnostic tools, clinical scales and studies available for the evaluation of the non-motor symptoms of the disease. Timely detection and proper management are essential for comprehensive treatment of persons with Parkinson’s disease.


REFERENCES

  1. Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017; En prensa.

  2. Kwon DY, Koh SB, Lee JH, Park HK, Kim HJ, Shin HW et al. The KMDS-NATION Study: Korean Movement Disorders Society Multicenter Assessment of Non-Motor Symptoms and Quality of Life in Parkinson’s Disease NATION Study Group. J Clin Neurol. 2016; 12 (4): 393-402.

  3. Rodríguez-Violante M, Cervantes-Arriaga A. Detection and management of non-motor symptoms in Parkinson’s disease: impact on their prevalence. Rev Med Chil. 2011; 139 (8): 1032-1038.

  4. De Saráchaga AJ, Cervantes-Arriaga A, Llorens-Arenas R, Calderón-Fajardo H, Rodríguez-Violante M. Change in motor and nonmotor symptoms severity in a “Real-Life” cohort of subjects with Parkinson’s disease. Neurosci J. 2015; 2015: 368989.

  5. Cosentino C, Nuñez Y, Torres L. Frequency of non-motor symptoms in Peruvian patients with Parkinson’s disease. Arq Neuropsiquiatr. 2013; 71 (4): 216-219.

  6. Romenets SR, Wolfson C, Galatas C, Pelletier A, Altman R, Wadup L et al. Validation of the non-motor symptoms questionnaire (NMS-Quest). Parkinsonism Relat Disord. 2012; 18 (1): 54-58.

  7. Khedr EM, El Fetoh NA, Khalifa H, Ahmed MA, El Beh KM. Prevalence of non motor features in a cohort of Parkinson’s disease patients. Clin Neurol Neurosurg. 2013; 115 (6): 673-677.

  8. Rodríguez-Violante M, Cervantes-Arriaga A, Villar-Velarde A, Corona T. Prevalence of non-motor dysfunction among Parkinson’s disease patients from a tertiary referral center in Mexico City. Clin Neurol Neurosurg. 2010; 112 (10): 883-885.

  9. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson’s disease. Mov Disord. 1990; 5 (4): 280-285.

  10. Karlsen KH, Larsen JP, Tandberg E, Maland JG. Influence of clinical and demographic variables on quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999; 66 (4): 431-435.

  11. De Cock VC, Vidailhet M, Leu S, Texeira A, Apartis E, Elbaz A et al. Restoration of normal motor control in Parkinson’s disease during REM sleep. Brain. 2007; 130 (Pt 2): 450-456.

  12. Postuma RB, Gagnon JF, Rompré S, Montplaisir JY. Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease. Neurology. 2010; 74 (3): 239-244.

  13. Alatriste-Booth V, Rodríguez-Violante M, Camacho-Ordoñez A, Cervantes-Arriaga A. Prevalence and correlates of sleep disorders in Parkinson’s disease: a polysomnographic study. Arq Neuropsiquiatr. 2015; 73 (3): 241-245.

  14. Haehner A, Boesveldt S, Berendse HW, Mackay-Sim A, Fleischmann J, Silburn PA et al. Prevalence of smell loss in Parkinson’s disease-a multicenter study. Parkinsonism Relat Disord. 2009; 15 (7): 490-494.

  15. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters ECh, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol. 2004; 56 (2): 173-181.

  16. Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H. Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov Disord. 2007; 22 (6): 839-842.

  17. Stephenson R, Siderowf A, Stern MB. Premotor Parkinson’s disease:clinical features and detection strategies. Mov Disord. 2009; 24 (Suppl 2): S665-S670.

  18. Morley JF, Duda JE. Olfaction as a biomarker in Parkinson’s disease. Biomark Med. 2010; 4 (5): 661-670.

  19. Herting B, Schulze S, Reichmann H, Haehner A, Hummel T. A longitudinal study of olfactory function in patients with idiopathic Parkinson’s disease. J Neurol. 2008; 255 (3): 367-370.

  20. Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson’s disease. Brain. 2008; 131 (Pt 3): 642-650.

  21. Devos D, Kroumova M, Bordet R, Vodougnon H, Guieu JD, Libersa C et al. Heart rate variability and Parkinson’s disease severity. J Neural Transm. 2003; 110 (9): 997-1011.

  22. Rodríguez-Violante M, Cervantes-Arriaga A, García-Ibarra D, Corona T. Orthostatic response of blood pressure in patients with early Parkinson’s disease. Arch Cardiol Mex. 2013; 83 (2): 93-99.

  23. Magerkurth C, Schnitzer R, Braune S. Symptoms of autonomic failure in Parkinson’s disease: prevalence and impact on daily life. Clin Auton Res. 2005; 15 (2): 76-82.

  24. Knudsen K, Krogh K, Østergaard K, Borghammer P. Constipation in Parkinson’s disease: Subjective symptoms, objective markers, and new perspectives. Mov Disord. 2017; 32 (1): 94-105.

  25. Bago Rožanković P, Rožanković M, Vučak Novosel L, Stojić M. Nonmotor symptoms in de novo Parkinson disease comparing to normal aging. Clin Neurol Neurosurg. 2017; 155: 7-11.

  26. Isais-Millán S, Piña-Fuentes D, Guzmán-Astorga C, Cervantes- Arriaga A, Rodríguez-Violante M. Prevalence of neuropsychiatric disorders in drug-naive subjects with Parkinson’s disease (PD). Gac Med Mex; 152 (3): 357-363.

  27. Rodríguez-Violante M, Cervantes-Arriaga A, Berlanga-Flores C, Ruiz-Chow A. Prevalence and determinants of depression in Mexican patients with Parkinson’s disease. Clin Neurol Neurosurg. 2012; 114 (10): 1293-1296.

  28. Rodríguez-Violante M, González-Latapi P, Cervantes-Arriaga A, Martínez-Ramírez D, Velázquez-Osuna S, Camacho-Ordoñez A. Apathy and associated factors in Mexican patients with Parkinson’s disease. Neurol Sci. 2014; 35 (5): 729-734.

  29. Rodríguez-Violante M, Velázquez-Osuna S, Cervantes-Arriaga A, Corona-Vázquez T, de la Fuente-Sandoval C. Prevalence, associated factors and phenomenology of psychosis in patients with Parkinson’s disease. Gac Med Mex. 2015; 151 (2): 169-175.

  30. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010; 67 (5): 589-595.

  31. Rodríguez-Violante M, González-Latapi P, Cervantes-Arriaga A, Camacho-Ordoñez A, Weintraub D. Impulse control and related disorders in Mexican Parkinson’s disease patients. Parkinsonism Relat Disord. 2014; 20 (8): 907-910.

  32. Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017; 13 (4): 217-231.

  33. Hanagasi HA, Tufekcioglu Z, Emre M. Dementia in Parkinson’s disease. J Neurol Sci. 2017; 374: 26-31.

  34. Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord. 2011; 26 (10): 1814-1824.

  35. Martinez-Martin P, Falup-Pecurariu C, Rodriguez-Blazquez C, Serrano-Dueñas M, Carod Artal FJ, Rojo Abuin JM, Aarsland D. Dementia associated with Parkinson’s disease: applying the Movement Disorder Society Task Force criteria. Parkinsonism Relat Disord. 2011; 17 (8): 621-624.

  36. Stamey W, Davidson A, Jankovic J. Shoulder pain: a presenting symptom of Parkinson disease. J Clin Rheumatol. 2008; 14 (4): 253-254.

  37. Rodríguez-Violante M, Alvarado-Bolaños A, Cervantes-Arriaga A, Martinez-Martin P, Rizos A, Chaudhuri KR. Clinical determinants of Parkinson’s disease-associated pain using the king’s parkinson’s disease pain scale. Mov Disord Clin Pract. 2017; En prensa.

  38. Rodríguez-Violante M, de Saráchaga AJ, Cervantes-Arriaga A, Millán-Cepeda R, Leal-Ortega R, Estrada-Bellmann I et al. Selfperceived pre-motor symptoms load in patients with Parkinson’s disease: a retrospective study. J Parkinsons Dis. 2016; 6 (1): 183-190.

  39. Siderworf A, Jennings D, Eberly S, Oakes D, Hawkins KA, Acherio A et al; PARS Investigators. Impaired olfaction and other prodromal features in the Parkinson at-risk syndrome study. Mov Disord. 2012; 27 (3): 406-412.

  40. Dahodwala N, Kubersky L, Siderworf A, PARS investigators. Can a screening questionnaire accurately identify mild parkinsonian signs? Neuroepidemiology. 2012; 39 (3-4): 171-175.

  41. Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K; PARS Investigators. Imaging prodromal Parkinson disease. Neurology. 2014; 83 (19): 1739-1746.

  42. Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol. 2011; 95 (4): 629-635.

  43. Berg D, Godau J, Seppi K, Behnke S, Liepelt-Scarfone I, Lerche S et al; PRIPS study group. The PRIPS study: screening battery for subjects at risk for Parkinson’s disease. Eur J Neurol. 2013; 20 (1): 102-108.

  44. Berg D. Tuebinger evaluation of risk factors for early detection of neurodegeneration. Parkinsonism Relat Disord. 2012; 18 (Suppl 1): S195-S198.

  45. Gaenslen A, Wurster I, Brockmann K, Huber H, Godau J, Faust B et al. Prodormal features for Parkinson’s disease-baseline data from the TREND study. Eur J Neurol. 2014; 21 (5): 766- 772.

  46. Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Knowles CH, Hardy J et al. PREDICT-PD: identifying risk of Parkinson’s disease in the community: methods and baseline results. J Neurol Neurosurg Psychiatry. 2014; 85 (1): 31-37.

  47. Estrada-Bellmann I, Camara-Lemarroy CR, Calderon-Hernandez HJ, Rocha-Anaya JJ, Villareal-Velazquez HJ. Non-motor symptoms and quality of life in patients with Parkinson’s disease in Northeastern Mexico. Acta Neurol Belg. 2016; 116 (2): 157- 161.

  48. Rodríguez-Violante M, Cervantes-Arriaga A, Corona T, Martínez- Ramírez D, Morales-Briceño H et al. Clinical determinants of health-related quality of life in Mexican patients with Parkinson’s disease. Arch Med Res. 2013; 44 (2): 110-114.

  49. Cervantes-Arriaga A, Rodríguez-Violante M, Villar-Velarde A, López-Gómez M, Corona T. Metric properties of clinimetric indexes for non-motor dysfunction of Parkinson’s disease in Mexican population. Rev Invest Clin. 2010; 62 (1): 8-14.

  50. Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, Rodriguez- Blazquez C, Alvarez-Sanchez M, Arakaki T et al. Assessing the non-motor symptoms of Parkinson’s disease: MDS-UPDRS and NMS Scale. Eur J Neurol. 2015; 22 (1): 37-43.

  51. Friedman JH, Alves G, Hagell P, Marinus J, Marsh L, Martinez- Martin P et al. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson’s disease. Mov Disord. 2010; 25 (7): 805- 822.

  52. Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE et al. Apathy and anhedonia rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2008; 23 (14): 2004-2014.

  53. Evatt ML, Chaudhuri KR, Chou KL, Cubo E, Hinson V, Kompoliti K et al. Dysautonomia rating scales in Parkinson’s disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson’s disease. Mov Disord. 2009; 24 (5): 635-646.

  54. Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE et al. Anxiety rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2008; 23 (14): 2015-2025.

  55. Fernandez HH, Aarsland D, Fénelon G, Friedman JH, Marsh L, Tröster AI et al. Scales to assess psychosis in Parkinson’s disease: Critique and recommendations. Mov Disord. 2008; 23 (4): 484-500.

  56. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S et al. Depression rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2007; 22 (8): 1077-1092.

  57. Rodríguez-Violante M, Lees AJ, Cervantes-Arriaga A, Corona T, Silveira-Moriyama L. Use of smell test identification in Parkinson’s disease in Mexico: a matched case-control study. Mov Disord. 2011; 26 (1): 173-176.

  58. Delgado G, Estañol B, Rodríguez-Violante M, Martínez-Memije R, Infante-Vázquez O, Bertado-Ramírez N. Cardiovascular variability in Mexican patients with Parkinson’s disease. Arq Neuropsiquiatr. 2014; 72 (10): 762-767.

  59. Brisinda D, Sorbo AR, Di Giacopo R, Venuti A, Bentivoglio AR, Fenici R. Cardiovascular autonomic nervous system evaluation in Parkinson disease and multiple system atrophy. J Neurol Sci. 2014; 336 (1-2): 197-202.

  60. Allio BA, Peterson AC. Urodynamic and physiologic patterns associated with the common causes of neurogenic bladder in adults. Transl Androl Urol. 2016; 5 (1): 31-38.

  61. Su A, Gandhy R, Barlow C, Triadafilopoulos G. Utility of highresolution anorectal manometry and wireless motility capsule in the evaluation of patients with Parkinson’s disease and chronic constipation. BMJ Open Gastroenterol. 2016; 3 (1): e000118.

  62. Lee HM, Koh SB. Many Faces of Parkinson’s disease: non-motor symptoms of Parkinson’s disease. J Mov Disord. 2015; 8 (2): 92-97.

  63. Ahlskog JE. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson’s disease. Mov Disord. 2005; 20 (3): 271-282.

  64. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014; 311 (16): 1670-1683.

  65. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R et al. The movement disorder society evidencebased medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2001; 26 (Suppl 3): S42-80.

  66. Mamikonyan E, Xie SX, Melvin E, Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebocontrolled study. Mov Disord. 2015; 30 (7): 912-918.

  67. Szeto JY, Lewis SJ. Current treatment options for Alzheimer’s disease and Parkinson’s disease dementia. Curr Neuropharmacol. 2016; 14 (4): 326-338.

  68. Combs BL, Cox AG. Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin. Neuropsychiatr Dis Treat. 2017; 13: 737-744.

  69. Goodarzi Z, Ismail Z. A practical approach to detection and treatment of depression in Parkinson disease and dementia. Neurol Clin Pract. 2017; 7 (2): 128-140.

  70. Martinez-Ramirez D, Okun MS, Jaffee MS. Parkinson’s disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists. Neurodegener Dis Manag. 2016; 6 (4): 319-330.




2020     |     www.medigraphic.com